The application of digital health to the assessment and treatment of substance use disorders: The past, current, and future role of the National Drug Abuse Treatment Clinical Trials Network

Lisa A. Marsch  
*Dartmouth College*, Lisa.A.Marsch@Dartmouth.edu

Aimee Campbell  
*Cynthia Campbell*  
*Dartmouth College*, Cynthia.I.Campbell@dartmouth.edu

Ching-Hua Chen  
*Ching-Hua.Chen@dartmouth.edu*

Emre Ertin

Follow this and additional works at: https://digitalcommons.dartmouth.edu/facoa

Part of the Computer Sciences Commons, and the Medicine and Health Sciences Commons

**Dartmouth Digital Commons Citation**

Marsch, Lisa A.; Campbell, Aimee; Campbell, Cynthia; Chen, Ching-Hua; Ertin, Emre; Ghitza, Udi; Lambert-Harris, Chantal; Hassanpour, Saeed; Holtyn, August F.; Hser, Yih-Ing; Jacobs, Petra; Klausner, Jeffrey D.; Lemley, Shea; Kotz, David; Meier, Andrea; McLeman, Bethany; McNeely, Jennifer; Mishra, Varun; Mooney, Larissa; Nunes, Edward; Stafylis, Chrysovalantis; Stanger, Catherine; Saunders, Elizabeth; Subramaniam, Geetha; and Young, Sean, "The application of digital health to the assessment and treatment of substance use disorders: The past, current, and future role of the National Drug Abuse Treatment Clinical Trials Network" (2020). *Open Dartmouth: Peer-reviewed articles by Dartmouth faculty*. 4017.  
https://digitalcommons.dartmouth.edu/facoa/4017

This Article is brought to you for free and open access by the Faculty Work at Dartmouth Digital Commons. It has been accepted for inclusion in Open Dartmouth: Peer-reviewed articles by Dartmouth faculty by an authorized administrator of Dartmouth Digital Commons. For more information, please contact dartmouthdigitalcommons@groups.dartmouth.edu.
Authors
Lisa A. Marsch, Aimee Campbell, Cynthia Campbell, Ching-Hua Chen, Emre Ertin, Udi Ghitza, Chantal Lambert-Harris, Saeed Hassanpour, August F. Holtyn, Yih-Ing Hser, Petra Jacobs, Jeffrey D. Klausner, Shea Lemley, David Kotz, Andrea Meier, Bethany McLeman, Jennifer McNeely, Varun Mishra, Larissa Mooney, Edward Nunes, Chrysovalantis Stafylis, Catherine Stanger, Elizabeth Saunders, Geetha Subramaniam, and Sean Young

This article is available at Dartmouth Digital Commons: https://digitalcommons.dartmouth.edu/facoa/4017
The application of digital health to the assessment and treatment of substance use disorders: The past, current, and future role of the National Drug Abuse Treatment Clinical Trials Network

Lisa A. Marsch⁎, Aimee Campbell, Cynthia Campbell, Ching-Hua Chen, Emre Ertin, Udi Ghitza, Chantal Lambert-Harris, Saeed Hassanpour, August F. Holty, Yih-Ing Hser, Petra Jacobs, Jeffrey D. Klausner, Shea Lemley, David Kotz, Andrea Meier, Bethany McLeman, Jennifer McNeely, Varun Mishra, Larissa Mooney, Edward Nunes, Chrysovalantis Stafylis, Catherine Stangera, Elizabeth Saunders, Geetha Subramaniam, Sean Young

⁎ Corresponding author at: Center for Technology and Behavioral Health, Geisel School of Medicine at Dartmouth College, 46 Centerra Dr, Lebanon, NH 03766, USA.
E-mail address: Lisa.A.Marsch@dartmouth.edu (L.A. Marsch).

Contents lists available at ScienceDirect

Journal of Substance Abuse Treatment

journal homepage: www.elsevier.com/locate/jsat

The application of digital technologies to better assess, understand, and treat substance use disorders (SUDs) is a particularly promising and vibrant area of scientific research. The National Drug Abuse Treatment Clinical Trials Network (CTN), launched in 1999 by the U.S. National Institute on Drug Abuse, has supported a growing line of research that leverages digital technologies to glean new insights into SUDs and provide science-based therapeutic tools to a diverse array of persons with SUDs.

This manuscript provides an overview of the breadth and impact of research conducted in the realm of digital health within the CTN. This work has included the CTN's efforts to systematically embed digital screeners for SUDs into general medical settings to impact care models across the nation. This work has also included a pivotal multi-site clinical trial conducted on the CTN platform, whose data led to the very first "prescription digital therapeutic" authorized by the U.S. Food and Drug Administration (FDA) for the treatment of SUDs. Further CTN research includes the study of telehealth to increase capacity for science-based SUD treatment in rural and under-resourced communities. In addition, the CTN has supported an assessment of the feasibility of detecting cocaine-taking behavior via smartwatch sensing. And, the CTN has supported the conduct of clinical trials entirely online (including the recruitment of national and hard-to-reach/under-served participant samples online, with remote intervention delivery and data collection). Further, the CTN is supporting innovative work focused on the use of digital health technologies and data analytics to identify digital biomarkers and understand the clinical trajectories of individuals receiving medications for opioid use disorder (OUD).

This manuscript concludes by outlining the many potential future opportunities to leverage the unique national CTN research network to scale-up the science on digital health to examine optimal strategies to increase the reach of science-based SUD service delivery models both within and outside of healthcare.
1. Introduction

Advances in digital technologies and data analytics have created unprecedented opportunities to assess and enhance health behavior and to accelerate the ability of science to understand and contribute to improved health behavior and health outcomes. Over 5 billion people in the world have access to mobile phone services (Silver, 2019). And access to these technologies is not confined to high income populations or countries but is also increasingly evident in many low and middle income countries and traditionally underserved populations (Collins et al., 2016; Deloitte, 2017; GSMA Intelligence, 2019; Mitchell & Kan, 2019; Naslund, Aschbrenner et al., 2017).

Digital health refers to the use of digital technologies and data analytics to understand people's health-related behavior and provide personalized health care resources (Bhavnani, Narula, & Sengupta, 2016; Dallery, Kurti, & Erb, 2015). Given the widespread access to technology worldwide, digital health offers great promise to enable widespread reach and scalability of evidence-based treatments to promote health behavior and collectively lead to transformations in the delivery of science-based health care.

The application of digital technologies to better assess, understand and treat substance use disorders (SUDs) is particularly promising and vibrant area of scientific research (Budney, Borodovsky, Marsch, & Lord, 2019; Marsch & Borodovsky, 2018; Marsch, Lord, & Dallery, 2014). Among the many applications of digital technologies, digital tools may be useful in the screening and assessment of SUD. Indeed, research evaluating the use of electronic screeners (e.g., assessments completed by a patient on a tablet) has demonstrated that individuals more accurately report risk behavior, including substance use and sexual risk behavior, when responding to questions posed by an electronic screener instead of by another individual (Perlis, Des Jarlais, Friedman, Arasteh, & Turner, 2004). Embedding standardized, validated clinical assessments of SUD into electronic health records may also facilitate the assessment and treatment of SUDs as part of the routine clinical workflow in a wide variety of clinical settings (Tai, Wu, & Clark, 2012).

Digital health interventions (called “digital therapeutics”) are interactive, self-directed software tools that can overcome some of the striking disparities in treatment access and treatment quality evident in healthcare settings across the globe (Hixson, 2015). For example, digital therapeutics can teach people effectively, scientifically validated skills to recognize and change unhealthy thoughts and behavior (such as drug use) and provide tools to help people apply these skills to their everyday lives. Digital therapeutics can be available 24/7 and thus allow for “on-demand” access to therapeutic support, thereby creating unprecedented models of intervention delivery and reducing barriers to accessing care. Treatments delivered via digital platforms can be widely accessible at a population level.

Telehealth, the use of telecommunication technologies to deliver long-distance clinical care, may also allow SUD expert clinicians to deliver care to communities (e.g., rural settings) where SUD treatment needs are high but SUD workforce capacity is limited (Lin et al., 2019). Telehealth can be used in concert with digital therapeutics to provide real-time distance communication with SUD clinicians via video technology, complemented by digital therapeutic software that does not rely on synchronous communication with another individual but rather can be available at all times.

Digital therapeutics and telehealth models of care may be transformative in the treatment of SUDs in many ways (Budney et al., 2019; Marsch, 2012; Marsch & Borodovsky, 2018; Marsch & Dallery, 2012; Rosa, Campbell, Miele, Brunner, & Winstanley, 2015). As most persons with SUDs spend the majority of their time outside of a treatment facility, digital technologies can extend the reach and impact of treatment by offering anytime/anywhere SUD care. Digital tools can function like a therapist “in your pocket” and can be accessible at times when individuals struggling with SUDs may be in greatest need of therapeutic support. Additionally, a large part of care offered in SUD treatment settings does not reflect the state of the science of SUD care (Center on Addiction, 2012). Digital therapeutics can ensure the delivery of SUD care with fidelity to the most evidence-based practices. Further, the behavioral health clinician workforce cannot meet the large population-level needs for SUDs or offer anytime/anywhere care (Hyde, 2013). Digital therapeutics provide science-based, scalable solutions to meet SUD needs at a population-level. This may be particularly relevant in tackling the current U.S. opioid crisis, in which the number of Americans with an opioid use disorder (OUD) has surged, especially in rural communities, while the trained SUD workforce has not grown at a comparable rate (Health Resources & Services Administration (HRSA), 2019).

Digital technologies also afford new opportunities to examine clinical trajectories and identify novel digital biomarkers within-individuals through intensive collection of individual-level data using mobile devices, wearable sensors, and mapping digital footprints. Indeed, digital tools may capture information about individual’s physiology “in vivo” as they live their daily lives (Jain, Powers, Hawkins, & Brownstein, 2015). Specifically, mobile technologies enable ecological momentary assessment (EMA; (Shiffman, Stone, & Hufford, 2008)) a method that prompts individuals to respond to queries on mobile devices, and which enables near real-time monitoring, of individuals’ behavior (including exposure to individual risk factors for drug use and drug-taking behavior) while they engage in daily activities. Because EMA allows for intensive longitudinal assessment in naturalistic contexts, these data offer promise to enhance our understanding of mechanisms of health behavior, including drug-taking behavior (McCarthy et al., 2008; Panilìo et al., 2019).

Digital technologies also enable passive sensing and inference from smartphones or sensing devices worn on the body, which is transforming how we understand human behavior (Cornet & Holden, 2018). Mobile sensing allows for the continuous measurement of physiological and behavioral data in the real world. This sensor data can be streamed to a smartphone and processed immediately to infer information about a person’s health behavior, physiology, and context. These data from sensors can be combined with data from self-report EMA assessments to enhance an understanding of the individual’s behavior in context (Marsch, 2018). This information can then be used to trigger the delivery of interventions in real time (e.g., to respond to a person’s in-the-moment needs, such as craving of a substance of abuse) (Burns et al., 2011; Gustafson et al., 2014).

Further, the use of social media sites (e.g., online forums, social blogs) has exploded in recent years. Social media enables multi-directional communication anywhere and anytime. Social media may be leveraged to recruit individuals into research, often allowing for rapid, cost-effective recruitment of national and hard-to-reach populations (Borodovsky, Marsch, & Budney, 2018; Reagan et al., 2019). Social media data have also been used to predict many phenomena, ranging from purchasing patterns to disease epidemics (Brownstein, Freifeld, & Madoff, 2009; Darden & Perreault, 1976), and a growing body of literature shows how social media data may enable a rich understanding of the topology and functioning of social networks and their relationships to health/risk behavior (Kazemi, Borsari, Levine, & Dooley, 2017; Kim, Marsch, Brunette, & Dallery, 2017; Naslund, Kim et al., 2017). For example, social media has been shown to contain signals of depression among individuals, such as decreased social activity, increased negative affect, highly clustered ego-centric networks, and heightened concerns about relations and medications (Choudhury, Gamon, Counts, & Horvitz, 2013). Also, data derived from social media has been shown to predict a range of sensitive personal attributes including sexual orientation, political views, personality traits, and use of addictive substances (Hassanpour, Tomita, DeLise, Crosier, & Marsch, 2019; Kosinski, Stillwell, & Graepel, 2013; Riccardi, Marsch, Crosier, & Hassanpour, 2018).

Digitally-derived data offer great potential to refine and advance
our understanding of health behavior, including SUDs. These granular-level data captured in daily life allow for the development of dynamic models of SUDs to understand behavior in real-time and in response to changing environmental, social, physiological, and intrapersonal factors (Naslund, Aschbrenner et al., 2017; Spruijt-Metz & Nilsen, 2014). And, they can help us understand when individuals may be most receptive to interventions (Nahum-Shani, Hekler, & Spruijt-Metz, 2015), with a goal of providing the right type/amount of therapeutic support at the right time by adapting to an individual’s changing internal and contextual state (Goldstein et al., 2017; Nahum-Shani et al., 2018).

Collectively, these digital technologies enable an entirely new offering of tools for collecting rich data about individuals’ behavior, health, and environment, provide personalized interventions and resources based on individuals’ needs and preferences, and enable dynamic computational models to predict and characterize individuals’ changing needs and health trajectories over time.

The National Drug Abuse Treatment Clinical Trials Network (CTN), launched in 1999 by the U.S. National Institute on Drug Abuse (NIDA), has supported a growing line of research that leverages digital technologies to glean new insights into SUDs and provide science-based therapeutic tools to a diverse array of persons with SUDs. The CTN is a unique research infrastructure for conducting practical, rigorous, and highly impactful trials focused on improving the treatment of SUDs and promoting widespread implementation and sustainability of effective and accessible SUD care in community systems across the nation. Among its many contributions, the CTN has supported a broad array of innovative and impactful research projects that have leveraged digital health.

This manuscript provides an overview of the digital health portfolio of the CTN and outlines a vision for the many future opportunities to leverage the unique national CTN research network to scale-up the science on digital health to examine optimal strategies to increase the reach of, and reduce barriers in access to science-based SUD service delivery models both within and outside of healthcare.

We reviewed the study designs and resulting publications from all studies (past and active) conducted on the CTN platform since its inception in 1999 (n = 107 CTN studies at the time of this writing). Studies that centrally included any of the following types of digital health technologies as a key part of the study aims or methods were identified and included in this overview: (1) digital SUD screening and/or assessment (n = 6), (2) digital therapeutics (n = 2), (3) telehealth (n = 2), (4) EMA and passive sensing technologies (n = 2, 5) social media platforms (n = 1). This manuscript is not intended to provide a comprehensive literature review of all the digital health studies conducted within the CTN but rather to provide an overview of the breadth and impact of the CTN’s work in the digital health space. For detailed information on every study within the CTN, the interested reader should visit: https://www.drugabuse.gov/about-nida/organization/cc/trn.

3. Results

3.1. CTN studies that employed digital SUD screening and/or assessment

The majority of digital health studies in the CTN have focused on the use of electronic health records (EHRs) for SUD screening and/or assessment. One of the earliest projects in this area was the development and validation of a brief screening and assessment instrument, the Tobacco, Alcohol, Prescription Medication, and Other Substance Use (TAPS) Tool, for use in primary care patients (CTN-0059). The TAPS tool is comprised of a 4-item screening survey, followed by a more detailed, substance-specific assessment of risk for any substances for which an individual has a positive initial screen (Wu et al., 2016). An early multi-site CTN trial with 2000 adult patients in 5 adult primary care clinics compared an interviewer-administered version of the TAPS tool to a version of the tool that was self-administered on a tablet computer (in which individuals had the option to hear questions read to them by a recorded voice on the computer) (McNeely et al., 2016). Results demonstrated that the interviewer- and self-administered versions of the TAPS tool had comparable diagnostic characteristics, but the self-administered version yielded higher rates of reporting of past year alcohol, illicit drug and prescription medication misuse (Gryczynski et al., 2017). The most notable discrepancy was for reports of prescription medication misuse, such that disclosure rates were 50% higher on the self-administered version. In addition, the tool showed promising sensitivity and specificity for detecting several types of substance use disorders, including tobacco and alcohol. It also identified adult primary care patients with high risk scores on the World Health Organization’s Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) as well as moderate risk scores for tobacco, alcohol and marijuana (Schwartz et al., 2017). Overall, the TAPS tool showed a more modest ability to identify some illicit and prescription medication SUDs in comparison to the ASSIST. Despite this, the TAPS tool is much briefer than the ASSIST and provides primary care providers with information about current substance use, thus underscoring its strong appeal for use in primary care. Given that visits to primary care represent an important window of opportunity to systematically screen and identify SUDs among a broad population (John et al., 2018; John et al., 2019; Wu et al., 2017), the TAPS tool is an example of a validated, brief and practical resource that can be routinely delivered, including in a digital format, in general medical settings. The TAPS tool is now available online for widespread use at: https://www.drugabuse.gov/taps/.

The CTN’s work has extended beyond development and validation of the TAPS SUD screening tool to evaluate the feasibility of embedding SUD screeners into EHRs in primary care and integrating screening into the primary care workflow. One trial (CTN-0065) evaluated how implementation of drug screening in primary care impacts rates of SUD assessment and subsequent care and demonstrated that screening led to an increase in SUD diagnoses, particularly cannabis use disorder diagnoses (Richards et al., 2019). Another multi-site study (CTN0062) being conducted in both urban primary care and rural Federally Qualified Health Centers (FQHCs) has identified barriers and facilitators of embedding screening into these settings and underscored the importance of clearly communicating with patients about the goals of screening to counteract stigma, addressing staff concerns regarding time and workflow, and providing SUD education and treatment resources to primary care clinicians (McNeely et al., 2018; Saunders et al., 2019). Several ongoing CTN projects have further extended this work to evaluate the feasibility, usability, acceptability (CTN-0076 and CTN-0090) and impact (CTN-0095) of OUD clinical decision support tools embedded in EHRs to help guide primary care providers in evidence-based treatment of OUD. Of considerable promise, and influenced by the research conducted within the CTN, the U.S. Preventive Services Task Force has just released a draft recommendation to screen for drug use among adults in general medical settings (U.S. Preventive Services...
3.3. CTN studies that employ telehealth

The CTN has had a marked impact in the field of digital therapeutics for SUDs – interactive software used to treat SUDs. The most impactful clinical trial with a digital therapeutic conducted within the CTN evaluated the clinical effectiveness of the web-based Therapeutic Education System (TES) (CTN-0044) (Campbell et al., 2014). TES is a web-based, self-directed version of the strongly evidence-based Community Reinforcement Approach (CRA) to behavior therapy (Bickel et al., 2008) developed by Azrin (1976). This intensive behavioral treatment is designed to teach individuals with SUDs how to better understand and disrupt harmful behaviors and cognitions related to their drug-taking behavior and to develop new skills to restructure their lives. In this pivotal CTN trial, the CRA-based behavioral treatment was offered along with incentives targeting drug abstinence and treatment participation. In this trial, conducted in partnership with 10 SUD treatment sites, individuals in outpatient SUD treatment were randomly assigned to receive either 12 weeks of standard outpatient SUD treatment or a treatment model in which TES partially replaced 2 h of patient-clinician therapy time or psychoeducation (approximately 2 h weekly). This study found that participants who received TES as part of their care model had a markedly lower rate of treatment dropout (hazard ratio = 0.72, 95% CI = 0.57, 0.92) and a higher rate of drug abstinence (odds ratio = 1.62, 95% CI = 1.12, 2.35), an effect that was most evident among patients who had a drug-positive urine and/or alcohol-positive breath screen at the time of entering the study (odds ratio = 2.18, 95% CI = 1.30, 3.68). This pattern highlighting the effectiveness of TES was evident across diverse groups of patients, including those with stimulant, cannabis and alcohol use disorders (Cochran et al., 2015), those with and without criminal justice involvement (Lee et al., 2017) those with and without Internet access (Tofghi et al., 2016), and across both males and females (Campbell et al., 2015) and diverse racial and ethnic groups (Campbell et al., 2017). TES was also found to have promising cost-effectiveness (Murphy et al., 2016).

This CTN trial built on a prior body of NIDA-funded single site trials showing, for example, that adding TES to buprenorphine treatment produces synergistic treatment effects; that replacing part of counselor-delivered treatment with TES treatment in methadone treatment systems greatly improves patients’ treatment outcomes, and that TES offered to incarcerated individuals can produce comparable treatment outcomes to those produced by exclusively clinician-delivered care (Bickel et al., 2008; Chaple et al., 2014, 2016; Christensen et al., 2014; Marsh et al., 2014). By conducting a national, highly rigorous multisite trial, the CTN study was well-poised to demonstrate the safety and effectiveness of the TES digital intervention when reviewed by the FDA, leading to the very first FDA-authorized prescription digital therapeutic in the U.S. (now called re-SET®, Pear Therapeutics). This reflects a new category of FDA-regulated devices and allows for digital therapeutics to be prescribed by clinicians, in a manner similar to FDA-approved medications. This is a compelling example of how CTN research can change the landscape of care to scale-up access to evidence-based treatments for SUDs.

This work led to several ancillary CTN studies focused on enhancing TES (in the form of a mobile app) to be modified for American Indians and Alaskan Natives (Campbell et al., 2015). And, several mobile digital therapeutics will be included in a new national CTN trial that will test strategies to improve treatment retention in medication treatment for OUD and to improve outcomes among individuals who are stabilized on OUD medications but wish to discontinue such medications (CTN-100).

3.4. CTN studies that employ ecological momentary assessment (EMA) and passive sensing technologies

Two CTN trials have employed EMA and passive sensing technologies. The first of these studies (CTN-0073-01) developed and evaluated the ability of a wrist-worn sensor suite (embedded in a smartwatch) to detect cocaine use (Holyn et al., 2019). This work builds on prior promising work demonstrating that a chestband with electrodes can detect cocaine use via a computational model that uses heart rate (interbeat intervals) and physical activity data (Hossain et al., 2014; Kennedy et al., 2015). The present study seeks to evaluate whether similar cocaine detection algorithms will work, that have been modified for use with sensor data collected via a less obtrusive, more user-friendly smartwatch that can be worn in daily life. Data from the smartwatch is compared to chestband data (because prior work demonstrated the chestband can detect cocaine use) as well as EMA reports of cocaine use (as “ground truth”) of cocaine use.

Cocaine use is often measured via self-report, which can be inaccurate, and/or use is measured via urine drug tests which can be intrusive and may not capture the temporal granularity of cocaine use patterns (Donovan et al., 2012). If smartwatch sensing is determined to be an acceptable and accurate way to measure cocaine use, it may offer rich information about the precise timing and duration of use events and could allow us to glean new insights into contextual factors that may serve as triggers for use events. Additionally, detecting cocaine use with greater precision may enhance our outcomes measurement in clinical trials that evaluate potential therapeutics for cocaine use disorder.

The second of these CTN studies (CTN-0084-A2) is, to our knowledge, the first study to employ passive mobile sensing, social media data, and active responses to queries on mobile devices using EMA to obtain moment-by-moment quantification of individual-level data (including contextual and momentary factors) that may lead to opioid use events, medication non-adherence and/or MOUD treatment dropout/retention (as measured via EHR data) in a population of persons with OUD in buprenorphine treatment.

In this study, participants are asked to wear a smartwatch and carry a smartphone continuously for a period of 12 weeks. The smartwatch passively collects data regarding location and distance traveled,
physical activity (including metrics of energy expenditure and steps), sleep, and heart rate. Participants are also prompted to respond to questions (EMA) through a smartphone multiple times per day. Questions assess sleep, stress, pain severity, pain interference, pain catastrophizing, craving, withdrawal, substance use risk context, mood, location, substance use, self-regulation, and MOUD adherence. In addition to the EMA prompts, individuals are asked to self-initiate EMAs if substance use occurred. App usage, audio/conversation, call/text, GPS, screen on/off, phone lock/unlock, phone notification information, Wi-Fi & Bluetooth logs, sleep, ambient light, and proximity are passively collected via smartphone. Participants are also asked if they are willing to share their social media data from any social media platforms they may use (e.g., Facebook, Instagram, Twitter). Sharing social media data is an optional component of study participation. The primary objective of the study is to evaluate the feasibility of utilizing digital health technology with OUD patients as measured by a 12-week period of continuous assessment using EMA and digital sensing. A secondary objective of this study is to examine the utility of EMA, digital sensing, and social media data (separately and compared to one another) in predicting OUD treatment retention and buprenorphine medication adherence.

Overall, this line of research may inform which subset(s) of digitally-derived data (digital biomarkers) may be most useful to employ as part of outcome measurement in future clinical trials research. Digital data that capture the richness of clinical status and clinically trajectories as individuals go about their daily lives may greatly complement and enhance the learning from standardized, clinical outcomes assessment. And predicting OUD treatment retention and medication adherence via continuous digital assessments may be used to identify early (and with relatively low participant burden) those participants who show signs of non-adherence and trigger additional intervention to prevent ultimate non-response to treatment.

3.5. CTN studies that employ social media platforms

In addition to the CTN-0084-A2 study referenced above which includes social media data as part of a broader set of digitally-derived data, the CTN supports a trial that centrally evaluates the relative utility of various social media platforms in recruiting a national sample from a hard-to-reach population. Specifically, this trial (CTN-0083) compares the relative effectiveness of using social media sites vs. online informational sites vs. online dating sites to promote HIV self-testing and seamless linkage to pre-exposure prophylaxis (PrEP) medication among young (aged 18–30), racial/ethnic minority, high-risk men who have sex with men (MSM). In this study, individuals in the targeted sample who click on culturally-tailored study advertisements and who provide online consent will be offered a free HIV self-test kit (OraSure®) to be discreetly sent to their home with seamless linkage to PrEP for those who test HIV-negative, and linkage to HIV care resources for those who test positive. Among other outcomes, the primary outcome is the monthly rate of study participants requesting an HIV home self-test kit per 30-day period by promotional platform (social media, informational, dating sites). The modifying role of substance use on observed outcomes will also be examined.

Online recruitment strategies allow for targeted recruitment of select audiences. The CTN-0083 study will target recruitment in the states that have hard-to-reach, high risk populations and limited availability of risk reduction services (e.g., Georgia, Louisiana, Maryland, Mississippi, and Nevada). This study illustrates how a targeted national sample can be recruited for clinical trials participation and how all intervention delivery and data collection in a clinical trial can be conducted remotely online.

4. Discussion

This manuscript provides an overview of the breadth and impact of research conducted within the U.S. National Drug Abuse Treatment Clinical Trials Network in the realm of digital health. This work has included the CTN’s efforts to systematically embed digital screeners for SUDs into general medical settings to increase the diagnosis and treatment of SUDs across the nation. This work has also included a pivotal multi-site clinical trial conducted on the CTN platform, whose data led to the very first “prescription digital therapeutic” authorized by the U.S. Food and Drug Administration (FDA) for the treatment of SUDs. Further CTN research includes the study of telehealth to increase capacity for science-based SUD treatment in rural and under-resourced communities. In addition, the CTN has supported an assessment of the feasibility of detecting cocaine-taking behavior via smartwatch sensing. The CTN has also supported the conduct of clinical trials entirely online (including the recruitment of national and hard-to-reach/under-served participant samples online, with remote intervention delivery and data collection). Further, the CTN is conducting innovative work focused on the use of digital health technologies and data analytics to identify digital biomarkers and understand the clinical trajectories of individuals with OUD in buprenorphine medication treatment for OUD.

Given its unique national research infrastructure and access to a broad array of community and healthcare partners, the CTN is uniquely poised to accelerate the scope and impact of its work applying digital health to the assessment and treatment of SUDs. Among these opportunities, the CTN is positioned to evaluate the role of digital technologies in SUD care transitions. For example, offering persons with SUDs access to a digital therapeutic and/or telehealth when they transition from a period of incarceration, hospitalization, or inpatient SUD care to the community would provide them with 24/7 access to therapeutic support as they reintegrate into the community and/or community-based care. Digital tools may also be offered directly to individuals recruited online who are not engaged, and do not wish to engage in SUD care within the healthcare system. Given that only about 10% of persons with SUDs are engaged in treatment, there is tremendous opportunity to creatively use digital technology to provide the other 90% with evidence-based SUD resources (Center for Behavioral Health Statistics and Quality, 2016).

The CTN is optimally poised to conduct national implementation science trials and/or hybrid implementation-effectiveness trials to evaluate optimal strategies to implement and sustain digitally-enhanced models of care. Such trials could integrate the various digital health tools and approaches that the CTN has previously studied in separate studies to instead embed a suite of complementary digital tools spanning an entire model of care within an integrated implementation strategy. That is, a digitally-enhanced model of care could include digital screeners and assessments in medical settings, linkage to electronic clinical decision support tools to enhance providers’ ability to deliver state-of-the-science care, as well as provision of digital therapeutics that are available directly to patients to ensure evidence-based care is available to them anytime and anywhere and can complement the care they receive in the healthcare sector. Importantly, digital therapeutics offered to patients do not need to reflect static models of behavioral treatment that work exactly the same way with every end user. Rather, these tools can be adaptive and flexibly offer evidence-based therapeutic resources to individuals that are responsive to their changing clinical needs, preferences, and goals.

There is tremendous opportunity to integrate the science of digital assessment and digital therapeutics for SUDs to help us understand (in real time) when individuals may be most receptive to health promotion interventions. They can, in turn, inform optimal delivery of “Just-in-Time Adaptive Interventions” or in-the-moment interventions for SUDs that provide the right type/amount of therapeutic support at the right time (Nahum-Shani et al., 2015; Nahum-Shani et al., 2018). The large and diverse samples that can be recruited within the CTN offer many opportunities to conduct novel experimental approaches (e.g., Micro-Randomized Trials, Sequential Multiple Assignment Randomized Trials, Factorial Designs) to systematically investigate who would benefit from
which intervention and when (i.e., under what conditions), as well as to apply novel statistical machine learning methods to personalize SUD interventions at the individual level (Dempsey, Liao, Kumar, & Murphy, 2017; Walton, Nahum-Shani, Crosby, Klasnja, & Murphy, 2018).

Importantly digital therapeutics do not need to have a siloed focus on SUD treatment (Marsch, 2014). Indeed, we have the opportunity to maximize benefit from what digital technology offers to embrace the co-occurring needs of patients. Digital therapeutics can arguably embrace whatever combination of needs a patient may have. They may focus on, for example, SUD and mental health care, SUD and chronic pain management, SUD and infectious diseases such as HIV and hepatitis, and/or SUD care and care for chronic physical health conditions. Because patients typically do not experience SUD in isolation but often have many care needs and because various comorbidities interact in clinically meaningful ways (Druss & Walker, 2011; Hooten, 2016; Onyeka, Hoehn, Eien Em, Bi, & I., 2019; Schulte & Hser, 2014), digital technologies can transcend the artificial constraints of siloed care models to provide therapeutic resources across many health domains and disease states. Digital health offers great promise for increasing the breadth and potency of models of SUD healthcare delivery.

Although applying digital health to the assessment and treatment of SUDs offers great promise, many challenges remain in this work. Indeed, there is tremendous opportunity for expanding research focused on how to best balance the promise of digital health with its potential limitations. For example, we can examine ethical questions (Capon, Hall, Fry, & Carter, 2016; Labrique, Kirk, Westergaard, & Merritt, 2013) such as “how do we best ensure that the benefit of digital tools outweighs potential risks?” and “how do we best ensure protection of patient privacy and sensitive information while still allow for data to be shared (e.g., between persons in SUD treatment and their providers and/or support network) in accordance with patient preferences and treatment goals?” Additionally, some sources of digitally-derived data, although rich and often voluminous, may contain biases and/or methodological challenges (Codella, Partovian, Chang, & Chen, 2018; Olteanu, Castillo, Díaz, & Kiciman, 2019). For example, data collected via EMA questions on mobile devices or via computerized SUD screeners are based on individuals’ self-report and may be subject to reporting bias. Additionally, identifying the optimal source of “ground truth” when making inferences about behavior using mobile sensing data remains a challenge (National Academies of Sciences, 2018). And best practices in preserving privacy when capturing and analyzing sensitive data (e.g., para-linguistic aspects of speech captured on mobile devices; consumer-generated social media data) need to be prioritized (Pentland, Lazer, Brewer, & Heilbeck, 2009). Further, although many populations across the world are increasingly getting access to mobile devices, some populations (such as some populations with SUDs) may have inconsistent access to mobile technology and/or live in communities (e.g., rural settings) with limited connectivity (Collins et al., 2016). And, patient engagement with digital therapeutic tools is an ongoing challenge (Wagner et al., 2017). Further, although interest in digital therapeutics among providers and healthcare systems has markedly increased in recent years, challenges remain with implementation and sustainability as well as payment models of digital health tools in many health care contexts (Mesner et al., 2019). Indeed, as the application of digital health to SUDs continues to expand, it is important that we have a parallel examination of ways in which to support the optimal and pragmatic measurement of patient privacy and ethics and widespread implementation in digital health research.

Digital health and data analytics are transforming our world. As we consider the striking unmet SUD treatment needs as well as the variability in quality of SUD care across the national and global landscape, digital technologies promise to extend and enhance our SUD clinical workforce to make on-demand, state of the science SUD treatment a reality worldwide.

CRediT authorship contribution statement

Lisa A. Marsch: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Writing - original draft. Aimee Campbell: Funding acquisition, Investigation, Methodology, Project administration, Writing - review & editing. Cynthia Campbell: Funding acquisition, Investigation, Project administration, Writing - review & editing. Ching-Hua Chen: Investigation, Project administration, Methodology, Writing - review & editing, Software. Emre Ertin: Investigation, Methodology, Project administration, Writing - review & editing, Software. Udi Ghitza: Investigation, Project administration, Writing - review & editing. Chantal Lambert-Harris: Investigation, Project administration, Writing - review & editing. Saeed Hassanzpour: Investigation, Methodology, Project administration, Writing - review & editing, Software. August F. Holty: Investigation, Project administration, Writing - review & editing. Yih-Ing Hser: Funding acquisition, Methodology, Investigation, Project administration, Writing - review & editing. Petra Jacobs: Investigation, Project administration, Writing - review & editing. Jeffrey D. Klausner: Investigation, Methodology, Project administration, Writing - review & editing, Software. Andrea Meier: Investigation, Project administration, Writing - review & editing. Bethany McMahan: Funding acquisition, Investigation, Methodology, Project administration, Writing - review & editing. Edward Nunes: Funding acquisition, Investigation, Methodology, Project administration, Writing - review & editing. Chrysovalantis Stafylis: Investigation, Methodology, Project administration, Writing - review & editing. Catherine Stanger: Investigation, Methodology, Project administration, Writing - review & editing. Elizabeth Saunders: Investigation, Project administration, Writing - review & editing. Geetha Subramaniam: Investigation, Project administration, Writing - review & editing. Sean Young: Investigation, Methodology, Project administration, Writing - review & editing.

Acknowledgement

Research reported in this publication was supported by the National Institute on Drug Abuse of the National Institutes of Health under Award Numbers UG1DA040309 and P30DA029926. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Declaration of competing interest

LAM is affiliated with Pear Therapeutics, HealthSim, LLC, and Square2 Systems, Inc. Conflicts of interest are extensively managed by her academic institution, Dartmouth College.

References